Relmada Therapeutics (RLMD) Operating Expenses (2012 - 2026)

Relmada Therapeutics (RLMD) has reported Operating Expenses for 15 consecutive years, with $19.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 6.82% year-over-year to $19.5 million; the TTM figure through Mar 2026 stood at $60.3 million (down 23.73% YoY), while the FY2025 annual figure was $59.1 million, down 29.55% from the prior year.
• Operating Expenses retreated to $19.5 million in Q1 2026 per RLMD's latest filing, from $20.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $45.5 million in Q2 2022 and bottomed at $10.2 million in Q2 2025.
• Historically, Operating Expenses has averaged $25.1 million across 5 years, with a median of $23.0 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Expenses soared 71.99% — and 2025, when it plunged 55.12%.
• Relmada Therapeutics' Operating Expenses stood at $38.7 million in 2022, then sank by 30.68% to $26.8 million in 2023, then dropped by 28.9% to $19.1 million in 2024, then gained by 6.59% to $20.3 million in 2025, then slipped by 4.29% to $19.5 million in 2026.
• Business Quant data shows RLMD's Operating Expenses at $19.5 million in Q1 2026, $20.3 million in Q4 2025, and $10.3 million in Q3 2025.